Refractory Acute Myeloid Leukemia Pipeline Therapeutics Development Review H2 2015

Press Release   •   Dec 14, 2015 08:09 EST

This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H2, 2015 Pipeline Review of “Refractory Acute Myeloid Leukemia” addition with 75 market data tables and 16 figures, spread across 437 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by professional's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

4SC AG, AbbVie Inc., Actinium Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Amgen Inc., Arog Pharmaceuticals, Inc., Array BioPharma Inc., Astellas Pharma Inc., Astex Pharmaceuticals, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., BioLineRx, Ltd., Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Calithera Biosciences, Inc., Celgene Corporation, Cornerstone Pharmaceuticals, Inc., CTI BioPharma Corp., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., EpiZyme, Inc., Exelixis, Inc., F. Hoffmann-La Roche Ltd., FORMA Therapeutics, Inc., Fujifilm Corporation, GlaxoSmithKline Plc, Igenica Biotherapeutics, Inc., Incyte Corporation, Jiangsu Hansoh Pharmaceutical Co., Ltd., JW Pharmaceutical Corporation, Karyopharm Therapeutics, Inc., Kyowa Hakko Kirin Co., Ltd., Les Laboratoires Servier SAS, MacroGenics, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., NantKwest, Inc., Novartis AG, Otsuka Holdings Co., Ltd., Oxford BioTherapeutics Ltd, Pharma Mar, S.A., Polaris Pharmaceuticals, Inc., SpectraMab GmbH, Sunesis Pharmaceuticals, Inc., Synta Pharmaceuticals Corp., TaiGen Biotechnology Co., Ltd., Threshold Pharmaceuticals, Inc., Tolero Pharmaceuticals, Inc. and Verastem, Inc.

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license)

Drugs Profile Discussed in this Research:

4SC-202, AG-120, alvocidib hydrochloride, AMG-232, AMG-330, aNK Program, AT-9283, BI-836858, binimetinib, BL-8040, bortezomib, buparlisib hydrochloride, burixafor, cabozantinib s-malate, cafusertib hydrochloride, CB-839, CC-90007, Cell Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia, Cell Therapy to Target CD33 for Relapsed and Refractory Acute Myeloid Leukemia, Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies, CPI-613, crenolanib besylate, CWP-291, DFP-10917, DS-3032, E-6201, elesclomol, eltrombopag olamine, erlotinib hydrochloride, evofosfamide, FF-10501, ficlatuzumab, FLX-925, FT-1101, gilteritinib fumarate, GO-2032c, GSK-2879552, GSK-525762, Hu8F4, ibrutinib, IGN-523, ilorasertib, imatinib mesylate, indisulam, Iomab-B, KHK-2823, lenalidomide, lirilumab, lurbinectedin, MGD-006, midostaurin, MK-2206, napabucasin, OPB-51602, Oshadi D + Oshadi R, OX-001, pegargiminase, PIM-447, pinometostat, quizartinib dihydrochloride, RG-7775, ruxolitinib phosphate, S-055746, selinexor, selumetinib sulfate, TAK-659, temozolomide, TEN-010, tigecycline, tosedostat, trametinib dimethyl sulfoxide + uprosertib, Triplebody 19x16x19, ulocuplumab, venetoclax, vorinostat, vosaroxin and VS-4718


  • The report provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Refractory Acute Myeloid Leukemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Refractory Acute Myeloid Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Refractory Acute Myeloid Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Refractory Acute Myeloid Leukemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Diseases & treatment Market.

One of the parameters that can define the health of a person is indeed the absence of diseases. There are so many diseases that confront mankind today to make life uncomfortable. If you are the one suffering from a disease and looking ways to get rid of that, the good news is that medical science has the solution for you. There are various treatment methods that are available today to help you cure the disease effectively. There are various diseases & treatment methods that exist today for the better of mankind. Being healthy and enjoying life is really possible today with the evolution of so many treatment methods.

There are different types of diseases & treatment methods available to suit the different needs. In fact, there are different branches of medical science that deal with the different types of diseases. While cardiology deals with the problems related to heart, dermatology can help you with various skin related problems. Visiting one of the specialists in the field is very much advisable when confronted with a disease. Often on the occurrence of a problem, it is best to visit a physician who can diagnose the disease and suggest you the specialist you must visit for the specific treatment. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries